08:07 AM EDT, 06/24/2024 (MT Newswires) -- GSK (GSK) said Monday its application to expand the use of Jemperli with chemotherapy for adult patients with primary advanced or recurrent endometrial cancer has been accepted by the European Medicines Agency for review.

The agency's Committee for Medicinal Products for Human Use will review the medicine to make a recommendation to the European Commission, with approval expected in H1 next year, GSK said in a regulatory filing.

Shares of GSK were up 0.6% in recent Monday premarket activity.

Price: 40.74, Change: +0.26, Percent Change: +0.63